The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis
Abstract
UNLABELLED: Tumor necrosis factor alpha (TNFalpha) plays an important role in the pathogenesis of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. TNFalpha blockade is a potential therapy for these disorders. METHODS: An open-label, multi-center, prospective clinical trial in two subgroups was performed. Study I examined acute disease, either first presentation or relapse (Birmingham Vasculitis Activity Score [BVAS] > or = 10; n = 16); study II examined persistent disease (BVAS > or = 4; n = 16). Patients received infliximab (5 mg/kg) at 0, 2, 6, and 10 wk. Concomitant therapy in study I included prednisolone and cyclophosphamide. Study II patients continued their existing treatment regimens, with prednisolone tapered according to clinical status. RESULTS: Mean age was 52.4 yr, 53% of the patients were female, and follow-up was 16.8 mo. Twenty-eight patients (88%) achieved remission (14 per study group). BVAS decreased from 12.3 (confidence interval [CI] = 10.5 to 14.0) at entry to 0.3 (CI = 0.2 to 0.9) at wk 14 (P < 0.001). C-reactive protein (mg/L) decreased from 29.4 (CI = 16.8 to 42.0) at entry to 7.0 (CI = 3.3 to 10.9) by wk 14 (P = 0.001). Mean prednisolone dose (mg/d) in study II decreased from 23.8 (CI = 15.0 to 32.5) at entry to 8.8 (CI = 5.9 to 11.7) at wk 14 (P = 0.002). There were two deaths and seven serious infections. Relapse occurred in five patients (three in study II) after a mean of 27 wk. CONCLUSION: TNFalpha blockade with infliximab was effective at inducing remission in 88% of patients with antibody-associated systemic vasculitis and permitted reduction in steroid doses. Severe infections were seen in 21% of patients, and despite continued infliximab, 20% of initial responders experienced disease flares. Infliximab is a promising new therapy for vasculitis both as a component of initial therapy and in the management of refractory disease. These results need confirmation in larger randomized trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Wegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Self-citationBirmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationBinding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
Booth, A. D., Almond, M. K., Burns, A., Ellis, P., Gaskin, G., Neild, G. H., Plaisance, M., Pusey, C. D., & Jayne, D. R. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00025-8 · Cited by 504
Self-citationBartolucci, P. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1126 · Cited by 304
In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis
Noronha, I. L., Krüger, C., Andrassy, K., Ritz, E., & Waldherr, R. (1993) · Kidney International · doi:10.1038/ki.1993.98 · Cited by 282
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis
Lamprecht, P. (2002) · Rheumatology · doi:10.1093/rheumatology/41.11.1303 · Cited by 245
Cited by
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Hellmich, B., Flossmann, O., Gross, W. L., Bacon, P., Willem Cohen-Tervaert, J., Guillevin, L., Jayne, D., Mahr, A., Merkel, P. A., Raspe, H., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062711 · Cited by 633
Self-citationBSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
Lapraik, C., Watts, R., Bacon, P., Carruthers, D., Chakravarty, K., D’Cruz, D., Guillevin, L., Harper, L., Jayne, D., Luqmani, R., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem146a · Cited by 369
Self-citationAntineutrophil cytoplasmic antibodies
Bosch, X., Guilabert, A., & Font, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69114-9 · Cited by 354
Metadata
- Authors
- Booth, A., Harper, L., Hammad, T., Bacon, P., Griffith, M., Levy, J., Savage, C., Pusey, C., & Jayne, D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2004-03
- Volume
- 15
- Issue
- 3
- Pages
- 717-721
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2099096560
- Cited by
- 359
- References
- 19
- FWCI
- 31.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. https://app.cochat.ai/papers/10.1097/01.asn.0000114554.67106.28
- The paper
- Booth, A., Harper, L., Hammad, T., Bacon, P., Griffith, M., Levy, J., Savage, C., Pusey, C., & Jayne, D. (2004). Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000114554.67106.28
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.